Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Editas Medicine Reports 58% Mean HBG1/2 Promoter Editing At Five Months Using Single-Dose tLNP Delivery in Non-Human Primates

Author: Benzinga Newsdesk | June 12, 2025 03:26am

Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy.
Achievement supports development of a novel, in vivo approach to treating sickle cell disease and beta thalassemia.

Posted In: EDIT